12 Month Data Release Pres - Q& A, page-23

PR should know all about FDA stringent requirements
when he commits to overly optimistic timelines, as we keep hearing about what an experienced team of
staff and advisors he has on hand. Although I am
encouraged by information coming out of the most
recent webinar and Q&A, like TRod, I treat a lot of it
with a grain of salt. I think many here have been
lulled into a false of security that a CR is a lot less
likely, because of the likelihood of a China deal.

CR’s pop up when you least expect AND when you
most expect them. So many of the spec companies
I have invested in pull a CR out of the blue, despite
protestations that there is nothing to see here.

As I have asked before, why are we so afraid of a
CR (as long as we all have an equal opportunity to
participate). It will give us much better bargaining
power with a potential partner and the dilution is
almost irrelevant, when we all believe we have
such a potential blockbuster on our hands. All IMO.